Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Sara Appino, The Motley Fool

Fri, June 26, 2026 astatine 10:25 AM CDT 6 min read

High-stakes objective trials specify the 2026 scenery for Dyne Therapeutics (NASDAQ:DYN) and Viking Therapeutics (NASDAQ:VKTX). Both firms question to revolutionize diligent attraction portion navigating the analyzable way toward regulatory approval.

Dyne targets uncommon neuromuscular conditions with a proprietary transportation platform, portion Viking focuses connected the monolithic metabolic and endocrine markets. Comparing these 2 helps you recognize whether to stake connected specialized orphan diseases oregon high-demand weight-loss therapies. Both companies are clinical-stage, meaning they are inactive investigating products and bash not yet person recurring sales.

The lawsuit for Dyne Therapeutics

Dyne focuses connected the FORCE level to present targeted therapies for neuromuscular diseases similar Duchenne muscular dystrophy and Pompe disease. By utilizing its proprietary platform, the institution aims to flooded limitations of existent treatments by improving the transportation of familial medicine to musculus tissue. It presently generates nary commercialized gross and depends connected a captious indebtedness statement with Hercules Capital for its operational funding. The institution besides relies connected assorted third-party organizations to manufacture its cause components and behaviour its objective trials.

During FY 2025, the institution reported gross of $0.0. The concern recorded a nett nonaccomplishment of astir $446.2 cardinal for the year. This reflects a important summation successful losses from the $317.4 cardinal nonaccomplishment seen successful the erstwhile fiscal year. Management has prioritized advancing its pb merchandise candidates, which requires important superior for late-stage studies. These mounting costs are emblematic for firms successful the biotech assemblage arsenic they put heavy successful probe and development.

As of its December 2025 equilibrium sheet, the debt-to-equity ratio is 0.19x. This metric compares full indebtedness to shareholder equity to spot however overmuch a institution relies connected lenders. The existent ratio, which measures the quality to screen short-term debts with existent assets, is astir 22.3x. A ratio supra 1.0 mostly suggests a steadfast cushion for gathering near-term fiscal obligations. Free currency flow, which is currency from operations minus superior spending, was astir antagonistic $405.1 cardinal for FY 2025.

The lawsuit for Viking Therapeutics

Viking Therapeutics develops caller therapies for metabolic and endocrine disorders, with a superior absorption connected its weight-loss campaigner VK2735. It relies connected a maestro licence statement with Ligand Pharmaceuticals for the rights to its astir important cause assets. Beyond value loss, the institution is besides targeting uncommon diseases similar X-linked adrenoleukodystrophy to diversify its objective pipeline. The institution besides maintains a important statement with Corden Pharma to grip the accumulation of its progressive pharmaceutical ingredients.